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processes involved in infectious and non-
infectious TLR signaling in the kidney will 
provide the basis for future strategies to 
interfere with early tubular-cell dysfunc-
tion in kidney disease.
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Homocysteine targeting of plasma 
proteins in hemodialysis patients
DW Jacobsen1,2
Hyperhomocysteinemia, an independent, modifiable risk factor for 
cardiovascular disease, is found in most patients with end-stage renal 
disease. In this issue, Perna et al. examine the extent of protein-S-
linked and protein-N-linked homocysteinylation in uremic patients 
on hemodialysis and the effect of folate treatment on protein 
homocysteinylation. Their findings show that protein-N-linked 
homocysteinylation, but not S-linked homocysteinylation, can be 
normalized by folate therapy.
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There is little doubt that hyperhomo-
cysteinemia is an independent, modifi -
able risk factor for cardiovascular disease. 
However, there is considerable contro-
versy regarding the issues of causality 
and mechanism. Is homocysteine a stealth 
mediator of atherogenesis and disease 
progression, or is it merely an innocent 
marker of the disease process? Patients 
with end-stage renal disease (ESRD) 
generally have mild (>12 to 30 µmol/l 
plasma total homocysteine (tHcy)) to 
intermediate hyperhomocysteinemia (>30 
to 100 µmol/l tHcy), although a presenta-
tion with severe hyperhomocysteinemia 
(>100 µmol/l tHcy) is not uncommon. 
Th e hyperhomocysteinemic state signals 
a breakdown in the homeostatic proc-
esses that regulate homocysteine pro-
duction and consumption. In addition to 
the pathways that consume intracellular 
homocysteine, cells and tissues also export 
this cytotoxic amino acid to circulation to 
maintain a low intracellular steady-state 
concentration. Th e export route serves 
as an escape valve when the consumptive 
metabolic pathways suff er genetic and/or 
acquired insults.
This laboratory has studied the bio-
chemical fate of homocysteine in circula-
tion by in vitro modeling.1,2 Th e original 
intent of these studies was to mechanisti-
cally account for the formation of the enti-
ties that constitute plasma tHcy. Because 
of its highly reactive nature, there is very 
little free reduced homocysteine in cir-
culation, and disulfi de forms account for 
more than 95% of tHcy. We have pro-
posed a model, based on in vitro and in 
vivo studies, to account for the formation 
of these disulfi de forms.2 Small amounts 
(<5% of tHcy) of protein-N-linked homo-
cysteine are found in circulation in addi-
tion to the predominant disulfi de forms of 
homocysteine. Protein-N-linked homo-
cysteine is formed when homocysteine 
thiolactone enters circulation and reacts 
via its activated carbonyl group with an 
ε-amino group of lysine to form a stable 
amide bond.3 Post-translational cova-
lent modification of protein by homo-
cysteine, whether it be N-linked (Figure 
1a) or S-linked (Figure 1b shows only one 
of several reactions leading to S-linked 
homocysteine as we have described1,2), 
has important mechanistic implications, 
as discussed below.
In this issue of Kidney International, 
Perna et al. examine plasma protein 
homocysteinylation in patients with 
ESRD, before and aft er treatment with N-
5-methyltetrahydrofolate.4 As expected, 
mean tHcy was elevated in hemodialysis 
patients compared with controls (57.8 
± 9.9 versus 11.4 ± 1.0 µmol/l). (Assays 
for tHcy measure protein-S-linked 
homocysteine and other disulfi de forms 
but do not measure protein-N-linked 
homocysteine. Therefore, currently 
available clinical diagnostic assays for 
plasma tHcy underestimate actual ‘total’ 
plasma homocysteine by 2%–5%.) Perna 
et al. then determined protein-N-linked 
and protein-S-linked homocysteine in 
controls and patients. Protein-S-linked 
homocysteine was 5.5-fold higher in 
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ESRD patients than in controls (52.0 ± 
9.16 versus 9.5 ± 1.2 µmol/l). In contrast, 
protein-N-linked homocysteine was only 
1.9-fold higher (0.68 ± 0.10 versus 0.35 
± 0.13 µmol/l). Very similar results were 
previously reported by Uji et al.5 A subset 
of hemodialysis patients was treated with 
oral N-5-methyltetrahydrofolate (15 mg) 
after each dialysis session for a period 
of 2 months. Patients with chronic renal 
failure are generally refractive to homo-
cysteine-lowering protocols, and, not 
unexpectedly, tHcy was lowered but not 
normalized in this study (mean tHcy = 
69.4 ± 15.2 µmol/l before therapy versus 
29.1 ± 4.0 µmol/l aft er therapy). Interest-
ingly, protein-N-linked homocysteine 
appeared to be normalized after treat-
ment (0.86 ± 0.14 µmol/l before and 0.40 
± 0.06 µmol/l aft er therapy).
Post-translational modification of 
proteins by homocysteine, whether it 
be N-linked or S-linked, has important 
mechanistic implications with respect to 
cardiovascular and other disease states.6 
Th is laboratory has identifi ed extracel-
lular proteins that undergo facile homo-
cysteinylation. Plasma fibronectin is 
S-homocysteinylated by l-homocysteine 
with the incorporation of five mol-
ecules of homocysteine per molecule of 
fi bronectin.7 Limited tryptic digests of the 
homocysteinylated fi bronectin followed 
by liquid chromatography/electrospray 
ionization/tandem mass spectrometry 
show that the homocysteine clusters in the 
C-terminal fibrin-binding domain. S-
linked homocysteinylation of fi bronec-
tin inhibits its ability to bind to fi brin, 
which could result in impaired fibri-
nolysis and lead to prolonged recovery 
from a thrombotic event.7 Th e amyloid 
protein transthyretin (prealbumin) is S-
homocysteinylated in vivo, as we recently 
demonstrated by immunoprecipitation 
and liquid chromatography/electrospray 
ionization/tandem mass spectrometry.8 
Transthyretin-S-homocysteine was 
detected in plasma from normal subjects, 
patients with ESRD, and patients with 
homocystinuria. The degree of homo-
cysteinylation in transthyretin from these 
subjects and patients was directly propor-
tional to tHcy levels. Transthyretin circu-
lates as a homotetramer, and each subunit 
contains a single cysteine residue at posi-
tion 10. Th e four cysteine residues in the 
homotetramer are not involved in inter-
chain disulfi de bond formation. Th us, the 
site of S-linked post-translational modi-
fi cation by homocysteine is well defi ned 
in this protein. Th e amyloidogenicity of 
transthyretin is enhanced by S-linked 
modifi cation with cysteine, cysteinylgly-
cine, or glutathione, but this has not been 
determined with transthyretin-Cys10-
S-S-homocysteine.9 Fibronectin and tran-
sthyretin are examples of plasma proteins 
that undergo S-linked homocysteinylation 
with possible functional consequences.
Plasma albumin is perhaps the most 
important player in homocysteine home-
ostasis and in hyperhomocysteinemia. 
Of the 35 cysteine residues in albumin, 
34 form intrachain disulfi de bonds and 
have important functions in maintain-
ing structural integrity of the molecule. 
Th e only free cysteine residue in albumin 
is found at position 34, and this residue 
forms disulfi de complexes not only with 
homocysteine, but also with cysteine 
(~60% of plasma total cysteine is car-
ried on albumin), cysteinylglycine, and 
glutathione. Albumin-Cys34-S-S-homo-
cysteine accounts for approximately 
75%–80% of tHcy. Our model studies 
demonstrated that homocysteine rap-
idly displaces cysteine from albumin-
Cys34-S-S-cysteine.1 Th e mechanism for 
the formation of albumin-Cys34-S-S-
homocysteine, although somewhat com-
plex, involves primarily thiol/disulfi de 
exchange and not autooxidation chem-
istry.2 Our studies on albumin-S-linked 
homocysteinylation led to the ‘homo-
cysteine molecular targeting hypothesis’ 
as a mechanistic explanation of homo-
cysteine causality in atherogenesis.6
Are intracellular proteins targeted 
by homocysteine in hyperhomocystein-
emia? Although numerous proteins have 
been proposed as potential targets for 
homocysteine, there is, as yet, no con-
vincing in vivo evidence of intracellular 
homocysteinylated proteins. Elevated 
homocysteine has been implicated in 
the generation of oxidative stress, in 
endoplasmic reticulum stress leading to 
the unfolded protein response, in lim-
ited bioavailability of nitric oxide, and 
in conversion of an anticoagulant phe-
notype to a procoagulant phenotype. 
Th e antioxidant defense system involv-
ing glutathione peroxidase 1 is a possi-
ble target of homocysteine, but it is not 
entirely clear whether the targeting is at 
the level of transcription, translation, or 
post-translation. Recent work by Handy 
et al. suggests that homocysteine directly 
interferes with translational processes 
involving insertion of selenocysteine into 
the nascent peptide.10 Homocysteine has 
also been implicated in the translational 
upregulation of folate receptors during 
folate defi ciency, which leads to hyper-
homocysteinemia. Antony et al. have 
proposed a mechanism whereby homo-
cysteine reacts directly with the cytosolic 
trans factor heterogeneous nuclear ribo-
nucleoprotein E1 (hnRNP E1) to increase 
its binding to an 18-base cis-element in 
the 5′-untranslated region of folate recep-
tor mRNA.11
It is premature to assess the relative 
importance of N-linked versus S-linked 
homocysteinylation in cardiovascular 
disease. It is likely that both processes are 
occurring in individuals with hyperhomo-
cysteinemia. One must consider, however, 
that more than 95% of the homocysteine in 
Figure 1 | Post-translational modification of plasma proteins by homocysteine. (a) Reaction 
between a protein lysine ε-amino group and homocysteine thiolactone.3 (b) Reaction between a 
protein cysteine thiolate anion and homocysteine–cysteine mixed disulfide.1
a b
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circulation is found as a disulfi de — either 
as a mixed disulfi de with protein, or as a 
low molecular species (homocystine and 
homocysteine–cysteine mixed disulfi de). 
Th erefore, effi  cacious treatment of hyperho-
mocysteinemia must result in the lowering 
of all disulfi de forms of homocysteine. As 
Perna et al.4 and others have shown, this is 
usually not possible in patients with ESRD 
when current therapeutic approaches are 
used. Patients with ESRD have much higher 
levels of tHcy than patients with coronary 
artery disease. A concerted eff ort is needed 
to identify homocysteinylated proteins in 
the ESRD patient population. Alternatively, 
experiments should be designed to isolate 
and identify homocysteinylated proteins 
from in vivo rather than in vitro settings. 
Protein homocysteinylation, whether it be 
N-linked or S-linked, may be the underly-
ing mechanism in homocysteine causality.
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Adenosine and dialysis 
hypotension
CFM Franssen1
In this issue, Imai et al. report the results of a double-blind placebo-
controlled study on the effect of an adenosine A1 receptor antagonist, 
FK352, on the incidence of dialysis hypotension in hypotension-prone 
patients. This Commentary discusses the use of selective adenosine A1 
receptor antagonists for the prevention of dialysis hypotension from the 
perspective of the potential role of adenosine in its pathogenesis.
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Dialysis hypotension
Dialysis hypotension is one of the most 
frequent complications of hemodialysis 
and can lead to serious vascular events 
such as cerebral, cardiac, and mesenteric 
ischemia or infarction. Frequent dialysis 
hypotension contributes to overhydration 
because of an inability to reach dry weight 
and may lead to underdialysis because of 
interruptions or early termination of the 
dialysis session.
Th e cause of dialysis hypotension is mul-
tifactorial. Th e basic concept, however, is 
that frank hypotension occurs only when 
cardiovascular compen satory mecha-
nisms do not adequately compensate for 
the inevitable blood volume reduction that 
results from the imbalance between the 
ultrafi ltration rate and the plasma refi lling 
rate.1 Sudden hypotension can be triggered 
especially by activation of the sympatico-
inhibitory cardiopressor refl ex (Bezold-Jar-
isch refl ex) in the context of a critical blood 
volume decline, impaired cardio vascular 
compensatory mechanisms, and cardiac 
underfi lling.2 Structural cardiovascular 
changes such as left  ventricular hypertro-
phy and diastolic dysfunction also play an 
important role, as these conditions oppose 
ventricular fi lling and predispose to a fall in 
end-diastolic volume and stroke volume.
Standard measures to prevent or alle-
viate dialysis hypotension include care-
ful assessment of dry weight, limitation 
of fl uid and salt intake, reduction of the 
dialysate temperature, abstinence from 
food during hemodialysis, use of bicar-
bonate instead of acetate as buff er in the 
dialysate, avoidance of low-sodium and 
low-calcium dialysate, and adjustment of 
the dosage and/or time of administration 
of antihypertensive drugs. Notably, one 
of the most eff ective strategies to prevent 
dialysis hypotension is to increase the 
dialysis time and/or the dialysis frequency, 
for example by short daily hemodialysis 
or frequent nocturnal (home) hemodialy-
sis. Finally, several classes of drugs have 
been reported to decrease the incidence 
of dialysis hypotension: for instance, the 
selective α1 adrenergic agonist midodrine, 
the norepinephrine precursor l-threo-3,4-
dihydroxyphenylserine (L-DOPS), and 
the selective serotonin reuptake inhibi-
tor sertraline hydrochloride. Imai et al.3 
(this issue) now add a new class of drugs, 
the adenosine A1 receptor antagonists, to 
the therapeutic arsenal to combat dialysis 
hypotension. Drug treatment for dialysis 
hypotension, however, should be consid-
ered only when the measures listed above 
fail to prevent hypotension.
Adenosine
Adenosine is an endogenous purine nucle-
oside with vasodilating, cardio depressant, 
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